363 related articles for article (PubMed ID: 25625417)
1. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
Cui YH; Chen J; Xu T; Tian HL
Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
Chaube U; Bhatt H
Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
[TBL] [Abstract][Full Text] [Related]
3. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
4. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors.
Khanfar MA; Taha MO
J Chem Inf Model; 2013 Oct; 53(10):2587-612. PubMed ID: 24050502
[TBL] [Abstract][Full Text] [Related]
5. New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation.
Kist R; Caceres RA
J Biomol Struct Dyn; 2017 Dec; 35(16):3555-3568. PubMed ID: 27860549
[TBL] [Abstract][Full Text] [Related]
6. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
Lv X; Ma X; Hu Y
Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
[TBL] [Abstract][Full Text] [Related]
7. Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR).
Park H; Choe H; Hong S
Bioorg Med Chem Lett; 2014 Feb; 24(3):835-8. PubMed ID: 24393580
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
10. Consensus scoring model for the molecular docking study of mTOR kinase inhibitor.
Li DD; Meng XF; Wang Q; Yu P; Zhao LG; Zhang ZP; Wang ZZ; Xiao W
J Mol Graph Model; 2018 Jan; 79():81-87. PubMed ID: 29154212
[TBL] [Abstract][Full Text] [Related]
11. Recent developments of small molecule PI3K/mTOR dual inhibitors.
Liu YN; Wan RZ; Liu ZP
Mini Rev Med Chem; 2013 Dec; 13(14):2047-59. PubMed ID: 24195664
[TBL] [Abstract][Full Text] [Related]
12. Role of mTOR in glioblastoma.
Duzgun Z; Eroglu Z; Biray Avci C
Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
[TBL] [Abstract][Full Text] [Related]
13. Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site.
Kist R; Timmers LFSM; Caceres RA
J Mol Graph Model; 2018 Mar; 80():251-263. PubMed ID: 29414044
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
[TBL] [Abstract][Full Text] [Related]
15. Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays.
Wang L; Chen L; Yu M; Xu LH; Cheng B; Lin YS; Gu Q; He XH; Xu J
Sci Rep; 2016 Jan; 6():18987. PubMed ID: 26732172
[TBL] [Abstract][Full Text] [Related]
16. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches.
Mohd Rehan
J Mol Graph Model; 2015 Nov; 62():226-234. PubMed ID: 26500112
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the discovery of small molecule mTOR inhibitors.
Roychowdhury A; Sharma R; Kumar S
Future Med Chem; 2010 Oct; 2(10):1577-89. PubMed ID: 21426150
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR, molecular dynamics simulations and molecular docking studies of benzoxazepine moiety as mTOR inhibitor for the treatment of lung cancer.
Chaube U; Chhatbar D; Bhatt H
Bioorg Med Chem Lett; 2016 Feb; 26(3):864-874. PubMed ID: 26764189
[TBL] [Abstract][Full Text] [Related]
19. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Development of ATP-Competitive mTOR Inhibitors Using Computational Approaches.
Luo Y; Wang L
Curr Pharm Des; 2017 Nov; 23(29):4321-4331. PubMed ID: 28699534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
